Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) AstraZeneca Ongoing Budesonide, Glycopyrronium and Formoterol Fumarate 3 D5982C00008 King Abdulaziz University Hospital (Jeddah)
A randomized, double-blind placebo-controlled trial to evaluate the safety and efficacy of a SARS-CoV-2 inactivated vaccine among healthcare workers in Saudi Arabia KAIMRC Rejected SARS-CoV-2 inactivated vaccine (Candidate vaccine) - Sinovac 3 RC20/370/R King Abdulaziz Medical City NG (Riyadh)
"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2" Bayer Terminated BAY 80-6946/Copanlisib 3 BAY 80-6946 / 17322 KAUH-J
A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study McMaster University Completed haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) 3 Version date Sep-3-2013 KKUH
A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy Roche Terminated Bevacizumab+ Capecitabine 3 MO22223 KAH & OC
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission National Cancer Institution Ongoing RITUXIMAB 3 EA4151 King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer NRG Oncology King Faisal Specialist Hospital & Research Center Ongoing CISPLATIN (CISPLATYL ) 2 NRG-HN002 KFSH & RC-R
"A Randomized controlled Trial of Influenza Vaccine to Reduce Adverse Vascular Events" McMaster University Ongoing Vaxigrip 3 version 2 KKUH
"A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack [THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death] " AstraZeneca Completed Ticagrelor 3 D5134C00003 KFMC
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) Astrazeneca Ongoing Ticagrelor 3 D5136C00009 KFMC
View 281 - 290 From 712